Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.cian.co | |
Market Cap | 51.67 Cr. | |
Enterprise Value(EV) | 91.95 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.81 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 25.46 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 18.98 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 1.09 | Calculated using Price: 20.67 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 2.50 Cr. | 24,995,764 Shares |
FaceValue | 10 | |
About Cian Healthcare Ltd. | ||
The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky's. |
1 Day |
|
+3.83% |
1 Week |
|
+1.37% |
1 Month |
|
-7.91% |
3 Month |
|
+25.26% |
6 Month |
|
-0.65% |
1 Year |
|
-26.14% |
2 Year |
|
+1.28% |
5 Year |
|
|
10 Year |
|
4 years | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -7.53 | 0.1 | -10.51 | 4.06 | |
Return on Capital Employed (%) | 3 | 6.99 | 0.46 | 7.41 | |
Return on Assets (%) | -2.42 | 0.03 | -3.42 | 1.24 |
Particulars | 5 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 58 | 58 | 55 | 57 | 56 | |
Non Curr. Liab. | 50 | 41 | 41 | 38 | 37 | |
Curr. Liab. | 48 | 58 | 69 | 65 | 71 | |
Minority Int. | ||||||
Equity & Liab. | 157 | 157 | 166 | 160 | 163 | |
Non Curr. Assets | 94 | 88 | 84 | 76 | 84 | |
Curr. Assets | 54 | 63 | 79 | 74 | 79 | |
Misc. Exp. not W/O | 8 | 5 | 3 | 10 | ||
Total Assets | 157 | 157 | 166 | 160 | 163 |
Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 57 | 74 | 78 | 69 | |
Other Income | 1 | 0 | 1 | 1 | |
Total Income | 58 | 74 | 78 | 69 | |
Total Expenditure | -50 | -62 | -74 | -56 | |
PBIDT | 8 | 12 | 5 | 14 | |
Interest | -7 | -8 | -7 | -6 | |
Depreciation | -4 | -3 | -4 | -5 | |
Taxation | 0 | -1 | 0 | 0 | |
Exceptional Items | 0 | 0 | 0 | 0 | |
PAT | -4 | 0 | -6 | 2 | |
Minority Interest | |||||
Share Associate | |||||
Other Related Items | |||||
Consolidated Net Profit | -4 | 0 | -6 | 2 | |
Adjusted EPS | -2 | 0 | -2 | 1 |
Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -7 | 6 | 9 | 5 | |
Cash Fr. Inv. | -27 | 3 | 1 | 3 | |
Cash Fr. Finan. | 36 | -10 | -11 | -7 | |
Net Change | 1 | -1 | -1 | 0 | |
Cash & Cash Eqvt | 3 | 2 | 1 | 1 |
Tue, 19 Mar 2024
Receipt Of Adjudication Order Of Penalties Under Section 454(3) Read With 117 Of The Companies Act 2013. Receipt of Adjudication order of Penalties under Section 454(3) read with 117 of Companies Act 2013. |
Thu, 29 Feb 2024
Intimation Of Amendment Of Policies Intimation of Amendment of Policies |
Tue, 20 Feb 2024
Intimation Of Winning Of Tender Of Pharmaceutical And Medical Device Bureau Of India (PMBI) Intimation of winning of Tender of PMBI for supply of various Drugs and Medicines |
Thu, 28 Mar 2024 |
Opening at High |
Making Higher Highs for 2 Days |
High Decrease in 1 Month |
High Increase in 3 Months |
Closing Near 100 SMA |